Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024
Replimune Group (NASDAQ: REPL) announced that a late-breaking abstract presenting the primary analysis of the IGNYTE clinical trial has been selected for oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The presentation, titled 'Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti-PD-1-failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab,' will be delivered by Dr. Caroline Robert from Gustave Roussy Cancer Center on September 15, 2024. This presentation is part of the Mini Oral Session on Melanoma and other skin tumors, highlighting Replimune's progress in developing novel oncolytic immunotherapies.
Replimune Group (NASDAQ: REPL) ha annunciato che un abstract di grande importanza, presentando l'analisi principale del trial clinico IGNYTE, è stato selezionato per una presentazione orale al Congresso della Società Europea di Oncologia Medica (ESMO) 2024. La presentazione, intitolata 'Dati primari di efficacia, sicurezza e sopravvivenza del coorte di pazienti con melanoma che ha fallito il trattamento anti-PD-1 dal trial IGNYTE con RP1 combinato con nivolumab,' sarà tenuta dalla Dr.ssa Caroline Robert del Gustave Roussy Cancer Center il 15 settembre 2024. Questa presentazione fa parte della Mini Sessione Orale su Melanoma e altri tumori della pelle, evidenziando i progressi di Replimune nello sviluppo di nuove immunoterapie oncolitiche.
Replimune Group (NASDAQ: REPL) anunció que un resumen de última hora que presenta el análisis principal del ensayo clínico IGNYTE ha sido seleccionado para una presentación oral en el Congreso de la Sociedad Europea de Oncología Médica (ESMO) 2024. La presentación, titulada 'Datos primarios de eficacia, seguridad y supervivencia del grupo de pacientes con melanoma que fracasó en el tratamiento con anti-PD-1 del ensayo clínico IGNYTE con RP1 combinado con nivolumab,' será realizada por la Dra. Caroline Robert del Gustave Roussy Cancer Center el 15 de septiembre de 2024. Esta presentación es parte de la Mini Sesión Oral sobre Melanoma y otros tumores de piel, destacando el progreso de Replimune en el desarrollo de nuevas inmunoterapias oncolíticas.
Replimune Group (NASDAQ: REPL)은 IGNYTE 임상 시험의 주요 분석을 발표하는 늦은 발표 초록이 2024 유럽 온콜로지학회(ESMO)에서 구두 발표를 위해 선정되었다고 발표했다. 'RP1과 nivolumab의 병용 치료를 받은 anti-PD-1 실패 멜라노마 환자 등록 의도 코호트의 주요 효능, 안전성 및 생존 데이터'라는 제목의 발표는 2024년 9월 15일 Gustave Roussy 암센터의 Dr. Caroline Robert에 의해 진행된다. 이 발표는 멜라노마 및 기타 피부 종양에 대한 미니 구두 세션의 일부로, 새로운 온콜리틱 면역요법 개발에 대한 Replimune의 진행 상황을 강조한다.
Replimune Group (NASDAQ: REPL) a annoncé qu'un abstract de dernière minute présentant l'analyse principale de l'essai clinique IGNYTE a été sélectionné pour une présentation orale lors du Congrès de la Société Européenne d'Oncologie Médicale (ESMO) 2024. La présentation, intitulée 'Données d'efficacité, de sécurité et de survie primaires de la cohorte de patients atteints de mélanome ayant échoué au traitement anti-PD-1 de l'essai clinique IGNYTE avec RP1 associé au nivolumab,' sera effectuée par Dr. Caroline Robert du Gustave Roussy Cancer Center le 15 septembre 2024. Cette présentation fait partie de la Mini Session Orale sur le Mélanome et d'autres tumeurs cutanées, mettant en lumière les avancées de Replimune dans le développement de nouvelles immunothérapies oncolytiques.
Die Replimune Group (NASDAQ: REPL) gab bekannt, dass ein wichtiges Abstract, das die primäre Analyse der IGNYTE-Studie präsentiert, für eine mündliche Präsentation auf dem Europäischen Kongress für Medizinische Onkologie (ESMO) 2024 ausgewählt wurde. Die Präsentation mit dem Titel 'Primäre Wirksamkeits-, Sicherheits- und Überlebensdaten der in die Registrierung einbezogenen Patientenkohorte mit anti-PD-1-gescheitertem Melanom aus der IGNYTE-Studie mit RP1 in Kombination mit Nivolumab' wird von Dr. Caroline Robert vom Gustave Roussy Krebszentrum am 15. September 2024 gehalten. Diese Präsentation ist Teil der Mini-Oralsitzung zu Melanomen und anderen Hauttumoren und hebt Replimunes Fortschritte bei der Entwicklung neuartiger onkolytischer Immuntherapien hervor.
- Late-breaking abstract selected for oral presentation at ESMO Congress 2024
- Presentation focuses on primary analysis of IGNYTE clinical trial
- Study involves patients with anti-PD-1-failed melanoma, a significant unmet medical need
- None.
WOBURN, Mass., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that a late-breaking abstract presenting the primary analysis of the IGNYTE clinical trial has been selected for oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 being held September 13-17, 2024, in Barcelona.
Presentation Details:
Title: Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti-PD-1-failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab
Presentation Session Title: Mini Oral Session - Melanoma and other skin tumours
Presentation Number: LBA46
Date and Time: Sunday, September 15, 2024 at 3:45 – 3:50 p.m. CEST
Speakers: Caroline Robert, MD, PhD, Gustave Roussy Cancer Center
About RP1
RP1 (vusolimogene oderparepvec) is Replimune’s lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF, intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Forward Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the design and advancement of our clinical trials, the timing and sufficiency of our clinical trial outcomes to support potential approval of any of our product candidates, our goals to develop and commercialize our product candidates, patient enrollments in our existing and planned clinical trials and the timing thereof, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the coronavirus as a global pandemic and related public health issues and the Russian-Ukrainian and Israel-Hamas political and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
What is the IGNYTE clinical trial that Replimune (REPL) is presenting at ESMO 2024?
When and where will Replimune (REPL) present the IGNYTE trial results at ESMO 2024?
Who will be presenting Replimune's (REPL) IGNYTE trial results at ESMO 2024?
What type of cancer is being targeted in Replimune's (REPL) IGNYTE trial presented at ESMO 2024?
